{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:24:42Z","timestamp":1790623482328,"version":"4.1.0"},"reference-count":38,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To study the influence of anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) treatment on echocardiographic measures and concentrations of endothelin 1 (ET-1), interleukin 6 (IL-6), and amino-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) in a cohort of 23 female patients with rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We recruited 23 patients (mean age 51.3 \u00b1 1.55 yrs) with RA resistant to treatment with disease-modifying antirheumatic drugs and average disease duration of 7.1 \u00b1 1.0 years who had been selected to start treatment with the anti-TNF-\u03b1 antagonist infliximab. Transthoracic echocardiographic examinations were performed before the first infusion and repeated after 1 year of treatment. Data for age, sex, RA disease activity by Disease Activity Score (DAS28) and echocardiographic data, NT-proBNP, IL-6, ET-1, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and other routine laboratory data were collected before treatment and after 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Twelve months of treatment with infliximab resulted in reduction of RA activity (i.e., reduction of DAS and acute-phase reactants). There was increased left ventricle ejection fraction, from 58.5% before treatment to 63% after. Treatment with infliximab also resulted in significant reduction of ET-1 (1.26 fmol\/ml before treatment vs 0.43 fmol\/ml after), IL-6 (58.46 pg\/ml vs 3.46 pg\/ml), and NT-proBNP (43.06 fmol\/ml vs 14.78 fmol\/ml). These reductions were observed after just 4 months of treatment and remained significant until the termination of the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>In patients with RA, treatment with infliximab contributed significantly to increase in left ventricular ejection fraction. Improvement of cardiac function was shown by conventional echocardiography; there was reduction of biochemical markers of heart failure.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.110751","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T01:55:28Z","timestamp":1329357328000},"page":"701-706","source":"Crossref","is-referenced-by-count":54,"title":["Infliximab Treatment Increases Left Ventricular Ejection Fraction in Patients with Rheumatoid Arthritis: Assessment of Heart Function by Echocardiography, Endothelin 1, Interleukin 6, and NT-pro Brain Natriuretic Peptide"],"prefix":"10.3899","volume":"39","author":[{"given":"PRZEMYSLAW J.","family":"KOTYLA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALEKSANDER","family":"OWCZAREK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAROSLAW","family":"RAKOCZY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MACIEJ","family":"LEWICKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EUGENE J.","family":"KUCHARZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PAUL","family":"EMERY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"key":"2018112909274294000_39.4.701.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.7.668"},{"key":"2018112909274294000_39.4.701.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"2018112909274294000_39.4.701.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2004.09.004"},{"key":"2018112909274294000_39.4.701.4","first-page":"36","article-title":"Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis","volume":"30","author":"Wolfe","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909274294000_39.4.701.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342607"},{"key":"2018112909274294000_39.4.701.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.01099.x"},{"key":"2018112909274294000_39.4.701.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.08.012"},{"key":"2018112909274294000_39.4.701.8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1527-5299.2002.00724.x","article-title":"Immune and neurohormonal pathways in chronic heart failure","volume":"8","author":"Sharma","year":"2002","journal-title":"Congest Heart Fail"},{"key":"2018112909274294000_39.4.701.9","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000124490.27666.B2"},{"key":"2018112909274294000_39.4.701.10","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000077913.60364.D2"},{"key":"2018112909274294000_39.4.701.11","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000150734.79804.92"},{"key":"2018112909274294000_39.4.701.12","doi-asserted-by":"publisher","DOI":"10.1186\/ar1814"},{"key":"2018112909274294000_39.4.701.13","first-page":"211","article-title":"Who might be predisposed to the development of serious side effects when treated with TNF-alpha antagonist?","volume":"24","author":"Kotyla","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909274294000_39.4.701.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.04.027"},{"key":"2018112909274294000_39.4.701.15","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.080234"},{"key":"2018112909274294000_39.4.701.16","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.064386"},{"key":"2018112909274294000_39.4.701.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.10.034"},{"key":"2018112909274294000_39.4.701.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7492.625"},{"key":"2018112909274294000_39.4.701.19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707516"},{"key":"2018112909274294000_39.4.701.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2007.08.009"},{"key":"2018112909274294000_39.4.701.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2009.11.006"},{"key":"2018112909274294000_39.4.701.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2018112909274294000_39.4.701.23","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90771-X"},{"key":"2018112909274294000_39.4.701.24","doi-asserted-by":"publisher","DOI":"10.1186\/ar2442"},{"key":"2018112909274294000_39.4.701.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.23796"},{"key":"2018112909274294000_39.4.701.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.119412"},{"key":"2018112909274294000_39.4.701.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-008-1111-4"},{"key":"2018112909274294000_39.4.701.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.08.018"},{"key":"2018112909274294000_39.4.701.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.24148"},{"key":"2018112909274294000_39.4.701.30","first-page":"398","article-title":"Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: A multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity","volume":"35","author":"Kerekes","year":"2008","journal-title":"J Rheumatol"},{"key":"2018112909274294000_39.4.701.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.007740"},{"key":"2018112909274294000_39.4.701.32","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2010.25"},{"key":"2018112909274294000_39.4.701.33","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802363768"},{"key":"2018112909274294000_39.4.701.34","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000037521.71373.44"},{"key":"2018112909274294000_39.4.701.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.09.039"},{"key":"2018112909274294000_39.4.701.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.23281"},{"key":"2018112909274294000_39.4.701.37","unstructured":"Furian T Aguiar C Prado K Ribeiro RV Becker L Martinelli N Ventricular dysfunction and dilation in severe sepsis and septic shock: Relation to endothelial function and mortality. J Crit Care 2011 Aug 18. [E-pub ahead of print]"},{"key":"2018112909274294000_39.4.701.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-010-0275-y"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.110751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:13:01Z","timestamp":1543497181000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.110751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,1]]},"published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.3899\/jrheum.110751"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.110751","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,15]]}}}